Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue from amino acids and chemicals increased, supported by strong demand. The profitability of products for electronic materials remains in the process of improving, while higher raw material and fuel prices resulting from the situation in the Middle East increased cost of sales, resulting in an operating loss and ordinary loss. Revenue from pharmaceuticals decreased due to lower sales of active pharmaceutical ingredients and active pharmaceutical ingredient intermediates.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥8,739 million (YoY +11.7%) |
| Operating profit | ¥-23 million |
| Ordinary income | ¥-48 million |
| Profit attributable to owners of the parent | ¥331 million (YoY +101.0%) |
| Net income per share | ¥15.34 |
| Equity ratio | End of the current fiscal period 53.5 / End of previous period 52.4 |
| Total assets | ¥25,001 million |
| Net assets | ¥13,368 million |
| Cash flows from operating activities | ¥1,843 million |
| Cash flows from investing activities | ¥248 million |
| Cash flows from financing activities | ¥-1,129 million |
| Cash and cash equivalents at end of period | ¥1,845 million |
| Full-year earnings forecast | Net Sales ¥17,700 million (YoY +14.6%) / Operating profit ¥550 million (YoY +43.3%) / Ordinary income ¥500 million (YoY +64.8%) / Net income ¥600 million (YoY +91.5%) |
| Revision to Earnings Forecast | Net Sales Not disclosed → ¥17,700 million / Operating profit Not disclosed → ¥550 million / Ordinary income Not disclosed → ¥500 million / Net income Not disclosed → ¥600 million |
| Annual Dividend Forecast | ¥10 → ¥10（0.0%） |
| Regional sales | Domestic Current interim period ¥3,632 million / Same period of the previous year ¥3,255 million / Exports Current interim period ¥5,107 million / Same period of the previous year ¥4,565 million |
| Depreciation and amortization | ¥580 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of investment securities ¥524 million / Extraordinary loss Compensation paid ¥7 million, Loss on disposal of non-current assets ¥38 million |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 21,974,000 |
| Treasury Shares at Period-End | 308,279 |
| Factors Behind Changes in Business Performance | Revenue from amino acids and chemicals increased, supported by strong demand. The profitability of products for electronic materials remains in the process of improving, while higher raw material and fuel prices resulting from the situation in the Middle East increased cost of sales, resulting in an operating loss and ordinary loss. Revenue from pharmaceuticals decreased due to lower sales of active pharmaceutical ingredients and active pharmaceutical ingredient intermediates. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Net sales increased as demand for amino acids and chemicals remained strong, while cost of sales rose due to higher raw material and fuel prices resulting from the situation in the Middle East, in addition to the fact that the profitability of products for electronic materials remains in the process of improving. Interim net income benefited from a ¥524 million gain on the sale of investment securities.